literature suggest some interrelationship between the pathological changes of the mesenchymal tissue and an imbalance of the hyaluronidase-hyaluronic -acid system. In rheumatoid arthritis the viscosity of the joint exudate is lower than that of synovia in normal subjects (Robertson and others, 1940) . The degree of polymerization of the hyaluronic acid in such exudate is likewise lowered (Ropes and others, 1947) . It has also been shown that in rheumatoid arthritis the viscosity of the joint exudate can be increased by intra-articular injection of cortisone * (Bauer, 1950; Ekman and others, 1952) . The in vitro inhibitory action of the exudate on hyaluronidase is also appreciably enhanced after such an injection (Ekman and others, 1952) .
While studying various substances for their effect on the enzymatic breakdown of hyaluronic acid, it was found that certain polycondensed diphenylmethane and triphenylmethane derivatives possess the power strongly to inhibit such hydrolysis in vitro (Hahn, 1952) . Some of these substances were also tried in animal experiments and proved to be also strong inhibitors of hyaluronidase in vivo (FabinyiSzebehely and others, 1952) .
The purpose of the present investigation was to find whether these substances might be of any value in the treatment of rheumatoid arthritis.
Synthetic Hyaluronidase Inhibitors (SHI) Tested (1 (3) Compound 16 P (Polycondensed heptahydroxy-tricarboxy triphenyl-methane). This compound was derived from polycondensed methylenedi-4-resorcylic acid by substitution with 2.3.4-trihydroxy-6-carboxy phenyl radicals in the methylene groups. The inhibitory power of this substance is slightly less than that of Compound 7 P in vitro, but approximately the same in vivo. Its oral LD50 is 5-4 mg./g. in mice.
Material
The material consisted of 101 cases (36 males and 65 females) with rheumatoid arthritis treated in this Department. Of these, 85 were in-patients and sixteen outpatients. The ages ranged from 7 to 62 years (average 42). At the commencement of the trial the patients had had rheumatoid arthritis for I to 27 years (average 8) and had been suffering from an exacerbation for 2 to 72 months (average 12). All of them showed pronounced symptoms and signs of the disease which was in an active stage. The in-patients were receiving selective physiotherapy and 34 of them were being treated with gold compounds. Most of them were receiving salicylate. This treatment was stopped immediately before or soon after the commencement of the trial. As to the outpatients, all previous medication was suspended for the duration of the trial, but no changes in regimen were prescribed. At Altogether 751 joints were regularly studied in these fifty patients.*
In all patients the clinical effect produced was favourable. In one case the administration of the substance was interrupted after 3 days. Already within this time the regression of the pronounced symptoms-and signs of the joints recorded was striking. The abatement of the joint symptoms and signs is apparent from Table I . In 36 patients in whom the initial abatement of the symptoms could be dated with certainty, it occurred within 5 days on the average. The regression of the signs was usually demonstrable within 7 days. The rate of improvement of the peri-articular swelling was usually highest during the first 2 to 3 weeks of the SHI administration.
As seen from Table I , in most of the cases no pronounced reduction of the capsular swelling was obtained. We have shown that streptochinase in combination with streptodornase, when injected intra-articularly, breaks down any fibrin clots in the joints. This disintegration of the fibrin clots and aspiration of the joint exudate reduces capsular swelling to such an extent that the capsule appears practically normal on palpation. Therefore in some * Since the preparation of this paper for the press another ten out-patients have received similar doses with equally good results. Effective doses sometimes caused severe diarrhoea that made it necessary to stop the administration of the substance. Discussion The material was selected in such a manner that spontaneous improvement could be -excluded with reasonable certainty at the commencement of the trial. These requirements probably best fulfilled by long-standing cases, in patients suffering' from a fairly long exacerbation. In our series the patients had had rheumatoid arthritis for 8 years on the average and had been suffering from an exacerbation for about 12 months.
In order to facilitate the evaluation of any differences in the condition of the joints we selected only those with striking changes, particularly with marked peri-articular swelling.
Rheumatoid arthritis often responds favourably to ordinary hospital regimen, and the initial signs of improvement usually appear within a few weeks. In our series, however, definite improvement was generally already recorded within 7 days.
Of the patients who received Compound 21 P, sixteen were also treated simultaneously with gold compounds. No difference was observed between the clinical results obtained in the patients receiving gold compounds and those in the rest of the group.
Compounds 21 P and 7 P were tried on both inpatients an.d out-patients and produced equally good results in both. Compound 16 P was not administered to out-patients. The out-patients received no other kind of therapy and no changes in regimen were prescribed.
Suspension of salicylate administration,at the start of the trial was usually followed by a transient increase in the joint pain. This is because the compounds tested have practically no analgesic effect. The subsequent marked decrease in the severity of toe joint symptoms recorded after a few days' administration of the compounds must be interpreted as an improvement in the condition of the joint. This gave fairly accurate information about the onset of the effect of the compounds tested on the joint symptoms. Salicylate was a source of comfort to most of the patients. A few days after this drug was replaced by the SHI the joints became less painful than they had been during the previous salicylate administration. Although the patients themselves also noticed a decrease in the swelling of the joints, they did not feel quite satisfied. It is suggested that this may be ascribed to some euphoric effect possessed by salicylate but not by the substances tried.
Observations made in the present investigation suggested the following conclusions:
(1) Compound 21 P produces the most favourable clinical results and practically no iide-effects.
(2) Compound 7 P is the least effective clinically and is accompanied by practically no side-effects.
(3) Compound 16 P when given in effective therapeutic doses produces severe diarrhoea. 
